Addition Therapeutics announced a $106.5 million financing and detailed its Precise RNA‑Mediated Insertion of Transgenes (PRINT) platform, an all‑RNA, lipid nanoparticle‑based approach to insert therapeutic transgenes at a genomic 'safe site.' The company spun out of University of California, Berkeley research and says the technology uses retrotransposase biology to mediate targeted insertion without viral vectors. Addition positioned PRINT as a potentially more scalable path to durable gene therapies, highlighting enzymatic insertion via LNP delivery rather than traditional viral integrase systems. Investors including philanthropic and strategic backers funded the launch to advance preclinical programs and manufacturing scale. The company framed the platform as an alternative to viral vectors that could reduce immunogenicity and manufacturing constraints for chronic and rare diseases.